PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1982-1983
10.1097/01.hs9.0000851276.20930.ad